Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: A systematic chart review

Takahito Uchida, Takefumi Suzuki, Hitoshi Sakurai, Chisa Tsutsumi, Ryosuke Den, Masaru Mimura, Hiroyuki Uchida

研究成果: Article

4 引用 (Scopus)

抄録

Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to examine 10-year outcomes for outpatients with schizophrenia who were receiving a conventional depot antipsychotic. Maintenance of outpatient status for 10 years was considered as a favorable outcome. From the initial sample of 1587 outpatients, 90 patients who were receiving a depot antipsychotic were included in this study (mean±SD, age 44.0±13.0 years; men, N=54). Haloperidol decanoate, fluphenazine decanoate, fluphenazine enanthate, and haloperidol decanoate plus fluphenazine enanthate were used in 53 (58.9%), 29 (32.2%), seven (7.8%), and one (1.1%) patients, respectively. These depot antipsychotics accounted for 36.9% of the total antipsychotic dosage on average. Seventeen patients (18.9%) successfully maintained outpatient status for 10 years. The most frequent reason for dropout was 'hospitalization' (N=49, 54.4%), followed by 'referral to another clinic/hospital' (N=9, 10.0%) and 'side effects' (N=7, 7.8%). As only 36.9% of the chlorpromazine equivalents were administered through depot antipsychotics, it is difficult to draw any firm conclusion. Still, the data suggest that even depot antipsychotics may not sufficiently prevent relapse in the treatment of schizophrenia.

元の言語English
ページ(範囲)261-266
ページ数6
ジャーナルInternational Clinical Psychopharmacology
28
発行部数5
DOI
出版物ステータスPublished - 2013 9

Fingerprint

Antipsychotic Agents
Schizophrenia
Outpatients
Chlorpromazine
Hospitalization
Referral and Consultation
Maintenance
Recurrence

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

これを引用

@article{5c10cbb02690440ababce43643363ae6,
title = "Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: A systematic chart review",
abstract = "Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to examine 10-year outcomes for outpatients with schizophrenia who were receiving a conventional depot antipsychotic. Maintenance of outpatient status for 10 years was considered as a favorable outcome. From the initial sample of 1587 outpatients, 90 patients who were receiving a depot antipsychotic were included in this study (mean±SD, age 44.0±13.0 years; men, N=54). Haloperidol decanoate, fluphenazine decanoate, fluphenazine enanthate, and haloperidol decanoate plus fluphenazine enanthate were used in 53 (58.9{\%}), 29 (32.2{\%}), seven (7.8{\%}), and one (1.1{\%}) patients, respectively. These depot antipsychotics accounted for 36.9{\%} of the total antipsychotic dosage on average. Seventeen patients (18.9{\%}) successfully maintained outpatient status for 10 years. The most frequent reason for dropout was 'hospitalization' (N=49, 54.4{\%}), followed by 'referral to another clinic/hospital' (N=9, 10.0{\%}) and 'side effects' (N=7, 7.8{\%}). As only 36.9{\%} of the chlorpromazine equivalents were administered through depot antipsychotics, it is difficult to draw any firm conclusion. Still, the data suggest that even depot antipsychotics may not sufficiently prevent relapse in the treatment of schizophrenia.",
keywords = "antipsychotic, depot, dopamine D2 receptor, long-acting injection, schizophrenia",
author = "Takahito Uchida and Takefumi Suzuki and Hitoshi Sakurai and Chisa Tsutsumi and Ryosuke Den and Masaru Mimura and Hiroyuki Uchida",
year = "2013",
month = "9",
doi = "10.1097/YIC.0b013e328363aa5a",
language = "English",
volume = "28",
pages = "261--266",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics

T2 - A systematic chart review

AU - Uchida, Takahito

AU - Suzuki, Takefumi

AU - Sakurai, Hitoshi

AU - Tsutsumi, Chisa

AU - Den, Ryosuke

AU - Mimura, Masaru

AU - Uchida, Hiroyuki

PY - 2013/9

Y1 - 2013/9

N2 - Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to examine 10-year outcomes for outpatients with schizophrenia who were receiving a conventional depot antipsychotic. Maintenance of outpatient status for 10 years was considered as a favorable outcome. From the initial sample of 1587 outpatients, 90 patients who were receiving a depot antipsychotic were included in this study (mean±SD, age 44.0±13.0 years; men, N=54). Haloperidol decanoate, fluphenazine decanoate, fluphenazine enanthate, and haloperidol decanoate plus fluphenazine enanthate were used in 53 (58.9%), 29 (32.2%), seven (7.8%), and one (1.1%) patients, respectively. These depot antipsychotics accounted for 36.9% of the total antipsychotic dosage on average. Seventeen patients (18.9%) successfully maintained outpatient status for 10 years. The most frequent reason for dropout was 'hospitalization' (N=49, 54.4%), followed by 'referral to another clinic/hospital' (N=9, 10.0%) and 'side effects' (N=7, 7.8%). As only 36.9% of the chlorpromazine equivalents were administered through depot antipsychotics, it is difficult to draw any firm conclusion. Still, the data suggest that even depot antipsychotics may not sufficiently prevent relapse in the treatment of schizophrenia.

AB - Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to examine 10-year outcomes for outpatients with schizophrenia who were receiving a conventional depot antipsychotic. Maintenance of outpatient status for 10 years was considered as a favorable outcome. From the initial sample of 1587 outpatients, 90 patients who were receiving a depot antipsychotic were included in this study (mean±SD, age 44.0±13.0 years; men, N=54). Haloperidol decanoate, fluphenazine decanoate, fluphenazine enanthate, and haloperidol decanoate plus fluphenazine enanthate were used in 53 (58.9%), 29 (32.2%), seven (7.8%), and one (1.1%) patients, respectively. These depot antipsychotics accounted for 36.9% of the total antipsychotic dosage on average. Seventeen patients (18.9%) successfully maintained outpatient status for 10 years. The most frequent reason for dropout was 'hospitalization' (N=49, 54.4%), followed by 'referral to another clinic/hospital' (N=9, 10.0%) and 'side effects' (N=7, 7.8%). As only 36.9% of the chlorpromazine equivalents were administered through depot antipsychotics, it is difficult to draw any firm conclusion. Still, the data suggest that even depot antipsychotics may not sufficiently prevent relapse in the treatment of schizophrenia.

KW - antipsychotic

KW - depot

KW - dopamine D2 receptor

KW - long-acting injection

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84881555462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881555462&partnerID=8YFLogxK

U2 - 10.1097/YIC.0b013e328363aa5a

DO - 10.1097/YIC.0b013e328363aa5a

M3 - Article

C2 - 23820334

AN - SCOPUS:84881555462

VL - 28

SP - 261

EP - 266

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 5

ER -